Company Filing History:
Years Active: 2024
Title: Aimee M Deaton: Innovator in RNAi Therapeutics
Introduction
Aimee M Deaton is a prominent inventor based in Somerville, MA (US). She has made significant contributions to the field of RNA interference (RNAi) therapeutics. Her work focuses on innovative solutions for disorders associated with iron overload and ineffective erythropoiesis.
Latest Patents
Aimee holds a patent for her invention titled "Transmembrane protease, serine 6 (TMPRSS6) iRNA compositions and methods of use thereof." This patent relates to RNAi agents, specifically double-stranded RNA (dsRNA) agents that target the TMPRSS6 gene. The invention outlines methods for using these RNAi agents to inhibit the expression of the TMPRSS6 gene. It also addresses methods for preventing and treating TMPRSS6-associated disorders, including hereditary hemochromatosis, β-thalassemia, and neurodegenerative diseases such as Parkinson's and Alzheimer's.
Career Highlights
Aimee is currently employed at Alnylam Pharmaceuticals, Inc., where she continues to advance her research in RNAi technologies. Her work has the potential to impact the treatment of various genetic disorders and improve patient outcomes.
Collaborations
Aimee has collaborated with notable colleagues, including John Michael Gansner and James D McIninch, to further her research and development efforts in the field of RNAi therapeutics.
Conclusion
Aimee M Deaton is a trailblazer in the field of RNAi therapeutics, with a focus on addressing critical health challenges through innovative inventions. Her contributions are paving the way for new treatment options for patients with genetic disorders.